These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37266092)

  • 21. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis.
    Gupta AK; Foley KA; Mays RR; Shear NH; Piguet V
    Br J Dermatol; 2020 Feb; 182(2):287-299. PubMed ID: 31120134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodialysis and Kidney Transplantation as Predisposing Conditions to Onychomycosis.
    Filho AMS; Ventura CG; Criado PR; Del Negro GB; Freitas RS; Luiz OC; Giudice MC; Neto ED; Benard G
    Nephron; 2017; 137(1):38-46. PubMed ID: 28609764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results from a Phase 1/2 trial of BB2603, a terbinafine-based topical nano-formulation, in onychomycosis and tinea pedis.
    Fuhr R; Cook D; Ridden J; Nield K; Leigh E; Cook J; Davies-Strickleton H; Dobmeyer J
    Mycoses; 2022 Jun; 65(6):661-669. PubMed ID: 35466481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
    Sarifakioglu E; Seçkin D; Demirbilek M; Can F
    Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis.
    Gupta AK; Stec N; Bamimore MA; Foley KA; Shear NH; Piguet V
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):580-588. PubMed ID: 31746067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antifungal susceptibility testing of fungi in patients with onychomycosis.
    Abu El-Hamd M; Abd Elhameed MI; Shalaby MFM; Saleh R
    Dermatol Ther; 2020 May; 33(3):e13429. PubMed ID: 32304603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Study of Q-switched Nd:YAG Laser versus Itraconazole in Management of Onychomycosis.
    Kandpal R; Arora S; Arora D
    J Cutan Aesthet Surg; 2021; 14(1):93-100. PubMed ID: 34084015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of mycological and clinical factors on the course and results of treatment of mycotic infections in patients with recurrent onychomycosis].
    Ratajczak-Stefańska V
    Ann Acad Med Stetin; 2003; 49():161-71. PubMed ID: 15552846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.
    Bräutigam M; Nolting S; Schopf RE; Weidinger G
    BMJ; 1995 Oct; 311(7010):919-22. PubMed ID: 7580551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diversified treatments of Tinea unguium].
    Fukuda T
    Nihon Ishinkin Gakkai Zasshi; 2002; 43(2):85-9. PubMed ID: 12040365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging drugs for the treatment of onychomycosis.
    Gupta AK; Stec N
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):213-220. PubMed ID: 31652088
    [No Abstract]   [Full Text] [Related]  

  • 32. Onychomycosis: Rapid Evidence Review.
    Frazier WT; Santiago-Delgado ZM; Stupka KC
    Am Fam Physician; 2021 Oct; 104(4):359-367. PubMed ID: 34652111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy for onychomycosis: new and emerging treatments.
    Lipner SR
    Expert Opin Pharmacother; 2019 Apr; 20(6):725-735. PubMed ID: 30689469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis.
    Sigurgeirsson B; Ghannoum M
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1549-62. PubMed ID: 22876754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Onychomycosis: pathogenesis, diagnosis, and management.
    Elewski BE
    Clin Microbiol Rev; 1998 Jul; 11(3):415-29. PubMed ID: 9665975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relevant insights into onychomycosis' pathogenesis related to the effectiveness topical treatment.
    Costa PS; Mendes V; Veiga FF; Negri M; Svidzinski TIE
    Microb Pathog; 2022 Aug; 169():105640. PubMed ID: 35716926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
    Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
    Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case Report of Onychomycosis and Tinea Corporis Due to Microsporum gypseum.
    Fike JM; Kollipara R; Alkul S; Stetson CL
    J Cutan Med Surg; 2018; 22(1):94-96. PubMed ID: 28817957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey.
    Oz Y; Qoraan I; Oz A; Balta I
    Int J Dermatol; 2017 Jan; 56(1):68-74. PubMed ID: 27667305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total Dystrophic Onychomycosis of All the Nails Caused by Non-dermatophyte Fungal Species: A Case Report.
    Nikitha S; Kondraganti N; Kandi V
    Cureus; 2022 Sep; 14(9):e29765. PubMed ID: 36324367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.